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ARTICLE
High phenotypic variability in 
Gerstmann-Sträussler-Scheinker disease
Elevada variabilidade fenotípica na doença de Gerstmann-Sträussler-Scheinker
Jerusa Smid1, Adalberto Studart Neto1, Michele Christine Landemberger2, Cleiton Fagundes Machado2, 
Paulo Ribeiro Nóbrega3, Nathalie Henriques Silva Canedo4, Rodrigo Rizek Schultz5, Michel Satya Naslavsky6, 
Sérgio Rosemberg7, Fernando Kok1, Leila Chimelli4, Vilma Regina Martins2, Ricardo Nitrini1
Human spongiform encephalopathies, or prion diseases, are 
rare fatal neurodegenerative conditions associated with conver-
sion of prion protein (PrPC) to its misfolded pathogenic isoform 
(PrPsc)1. According to their etiology, prion diseases can be classified 
as sporadic, genetic or acquired by infection and their estimated 
annual incidence is approximately one per million individuals2,3,4. 
Genetic forms of prion diseases are inherited as an autosomal 
dominant trait and associated with mutations in the prion protein 
gene (PRNP), accounting for around 15% of cases5. The PRNP 
mutations lead to three major phenotypes: Creutzfeldt-Jakob 
disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) disease 
and familial fatal insomnia4.
Gerstmann-Sträussler-Scheinker disease was first 
reported in an Austrian family in 1936 and its main clini-
cal features are slowly progressive cerebellar ataxia asso-
ciated with cognitive decline6. The molecular basis of GSS 
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ABSTRACT
Gerstmann-Sträussler-Scheinker is a genetic prion disease and the most common mutation is p.Pro102Leu. We report clinical, molecular 
and neuropathological data of seven individuals, belonging to two unrelated Brazilian kindreds, carrying the p.Pro102Leu. Marked 
differences among patients were observed regarding age at onset, disease duration and clinical presentation. In the first kindred, two 
patients had rapidly progressive dementia and three exhibited predominantly ataxic phenotypes with variable ages of onset and disease 
duration. In this family, age at disease onset in the mother and daughter differed by 39 years. In the second kindred, different phenotypes 
were also reported and earlier ages of onset were associated with 129 heterozygosis. No differences were associated with apoE genotype. 
In these kindreds, the codon 129 polymorphism could not explain the clinical variability and 129 heterozygosis was associated with earlier 
disease onset. Neuropathological examination in two patients confirmed the presence of typical plaques and PrPsc immunopositivity.
Keywords: Gerstmann-Sträussler-Scheinker disease; prion diseases; prions.
RESUMO
A doença de Gerstmann-Sträussler-Scheinker é uma doença priônica genética, cuja mutação mais frequente é p.Pro102Leu. Descrevem-se 
dados clínicos, moleculares e neuropatológicos de sete indivíduos em duas famílias não relacionadas com p.Pro102Leu. Diferenças notáveis 
entre os pacientes em relação à idade de início, duração da doença e apresentação clínica foram encontradas. Na primeira família, dois 
pacientes apresentaram demência rapidamente progressiva e três apresentaram fenótipo de ataxia com idade variáveis de início e duração 
da doença. Nesta família, a idade de início entre mãe e filha diferiu em 39 anos. Na segunda família, fenótipos diferentes  foram observados 
e idades precoces de início dos sintomas foram associadas à heterozigose no códon 129. Não houve diferença em relação ao genótipo do 
gene da apoE. O genótipo do códon 129 não foi responsável pela variabilidade clínica; heterozigose no códon 129 esteve associada ao início 
precoce da doença. O exame neuropatológico em dois pacientes confirmou presença de placas típicas e imunohistoquímica para PrPsc.
Palavras-chave: doença de Gerstmann-Sträussler-Scheinker; doenças de prion; príons.
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was identified in 1989, when the substitution of a proline at 
position 102 for leucine (p.Pro102Leu) in the PRNP gene was 
recognized in two families7; this same variant was subse-
quently identified in the original Austrian family8. A number 
of other mutations associated with GSS were also reported, 
predominantly missense and nonsense pathogenic vari-
ants located at codons 105, 117, 131, 187, 198, 202, 212, 217, 
and 232, or copy number variation in octapeptide repeats9. 
The common variant in the PRNP gene, p.Met129Val, might 
act as a disease modifier in prion disease, but alone is not 
solely responsible for this condition. Clinical and pathologi-
cal phenotypic variability among individuals with the same 
mutation had previously been reported worldwide10,11,12,13,14. 
Several factors may contribute to this variability, such as 
the genotype for the variant p.Met129Val and differences in 
molecular prion strains14,15,16. A study conducted in the larg-
est reported GSS disease kindred confirmed marked pheno-
typic variability and suggested that the p.Met129Val variant 
genotype was associated with it14. 
In the present study, we report two unrelated Brazilian 
families with GSS disease due to a p.Pro102Leu mutation. 
Clinical, molecular and/or pathological data of five cases 
in one family and two cases in another family are reported. 
Age at onset ranged from 25 to 66 years old and disease dura-
tion ranged from eight months to 15 years.
METHODS
Patients
Two individuals from Brazilian families with clinical 
symptoms suggestive of prion disease were first evaluated, 
and GSS disease confirmed based on the finding of the vari-
ant p.Pro102Leu in one allele of the PRNP gene. Based on this 
diagnosis, data from other family members were collected 
and prospective follow-up performed. Where possible, fam-
ily members were interviewed, patients examined and blood 
samples taken for molecular analysis after informed consent. 
Additional investigations, such as brain MRI, protein 14.3.3 
in cerebrospinal fluid (CSF) and an electroencephalogram 
were performed when possible. This study was approved by 
the Institutional Ethics Committee and participating families 
signed the informed consent form.  
Genetic analysis
The DNA was extracted according to standard protocols 
using the Wizard Genomic DNA Purification Kit®. The PRNP 
coding region amplification and sequencing were performed 
adopting previously published procedures17. In order to 
investigate the segregation of the variants p.Pro102Leu and 
p.Met129Val, PCR products of the complete coding region 
of PRNP were cloned using pGEM®-T Easy Vector Systems 
(Promega) and then sequenced. For apolipoprotein E (apoE) 
gene analysis, allele-specific real-time PCR was performed18.
Brain tissue analyses
Formalin-fixed fragments of the cerebral cortex, basal 
ganglia, hippocampus and cerebellum were immersed in 
95% formic acid, and then processed for paraffin embedding. 
Histological sections were stained with H&E and Congo 
Red. Antigen retrieval was performed after tissue expo-
sure to 10mM citrate buffer, pH6.0 for 40 minutes at 96oC. 
Immunohistochemical studies were performed using anti-
PrPC monoclonal antibody (clone PrP3F4;DAKO) followed by 
Polymer Secondary System (Novolink, Leica). Unfortunately, 
there was no availability of frozen unfixed brain tissue for 
western blot analysis of protease-resistant prion protein.
RESULTS
Clinical descriptions
Family A
In this family, there were five affected individuals (ped-
igree shown in Figure 1). Clinical and/or pathological data 
of five patients over two generations are given in Table 1. 
In the first generation, the father of three affected individ-
uals died after the seventh decade of life while the mother 
died in her forties, without symptoms of GSS disease. 
Three siblings from the second generation, aged from 61 
to 69 years old, have no symptoms to-date. Fifteen rela-
tives of the third generation, aged from 27 to 51 years old, 
are also asymptomatic. 
Patient IIIa - 1 (index)
Disease onset occurred at the age of 27 years with 
rapid cognitive decline progressing to severe dementia in 
two years. Gait instability and dysarthria emerged after 
five years. Neurologic examination seven years after onset 
showed severe dementia, grasping reflex, parkinsonian 
gait with bilateral support, hyperactive tendon reflexes 
with Babinski sign, and plastic rigidity in the upper limbs. 
Myoclonus occurred eight months later. She died 15 years 
after the first symptoms.
Family B
This Brazilian family is from Portuguese descent and 
had six probably-affected individuals (pedigree shown 
in Figure 1). The first known case was the paternal 
grandfather of the proband (Ib - 1). He died before the age 
of 40 with a disease that rendered him dependent for sev-
eral years. In the next generation, there were reports of 
at least three individuals who died at around the fourth 
decade of life, with similar features. The father of the pro-
band (IIb - 1) died at age 33 after eight years of disease, 
with gait and speech impairment and cognitive decline. In 
the third generation, two patients were evaluated. Clinical 
data for these two patients are given in Table 1. 
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Patient IIIb – 1
Disease onset occurred at age 35 with cognitive decline 
and balance deficit. Severe dementia and abasia occurred 
three years later. Neurologic examination three years after 
onset revealed severe dementia with frontal syndrome and 
global cerebellar ataxia. Spasticity, brisk tendon reflexes in 
all four limbs and Babinski sign were also present. 
The age of onset in the two reported families ranged 
from 27 to 66 years old. The duration of the disease ranged 
from eight months to 15 years. The clinical diagnosis of pos-
sible CJD was initially proposed in two patients. Typical 
GSS features were observed in four patients (IIa-2, IIa-3, 
IIIa-2 and IIIb-2). 
Molecular data
The p.Pro102Leu mutation was found in all six patients 
(IIa-2, IIa-3, IIIa-1, IIIa-2, IIIb-1 and IIIb-2) who underwent 
genetic analyses. This investigation was not possible in 
one patient (IIa-1). Four patients were heterozygote at 
codon 129 (methionine/valine, Met129Val) and two were 
homozygote for methionine. All patients from family A 
were e3/e3 and all patients from family B were e2/e3 for 
apoE gene (Table 1).
Neuropathological data
Neuropathological study was performed in three of the 
five patients from family A. 
Spongiform encephalopathy was found on frontal lobe 
biopsy of patient IIa-1. At the time immunohistochemistry 
for PrPSc was not available, and the slides and blocks could 
not be retrieved for further studies. 
The study of patient IIIa-1 showed that focal neuronal 
loss, spongiosis and gliosis were minimal, both in the cerebral 
and the cerebellar cortex. However, there were multicentric 
plaques in the molecular layer of the cerebellum (Figure 2) 
and deep regions of the temporal cortex, including regions of 
the hippocampus, adjacent to pyramidal cells and granular 
cells of the dentate fascia (Figure 3). The basal ganglia, thal-
ami, midbrain, pons, and medulla were normal. 
In patient IIIa-2, there was severe diffuse cerebral and cere-
bellar cortical atrophy, in addition to extensive involvement of 
the subjacent white matter, which was rarefied and collapsed, in 
some areas containing small cavities (Figure 4). The basal gan-
glia and thalami were also extremely reduced in size. There was 
extensive neuronal loss, reactive gliosis and spongiosis, both in 
the cerebral and cerebellar cortex, with extensive Purkinje and 
granular cell loss.  The subjacent white matter was rarefied, 
Figure 1. Pedigree: A) Family A; B) Family B.
IIa - 1
Affected
IIa - 2
Affected
IIa - 2
Affected
IIIa - 1
Affected
IIa - 3
Affected
Ib - 1
Affected
Affected Affected Affected IIIb - 1
Affected
IIIb - 2
Affected
IIIb - 1
Affected
A
B
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Figure 2. Patient IIIa-1. Multicentric plaques in the molecular 
layer of the cerebellum.
300µm
Figure 3. Patient IIIa-1. Multicentric plaque adjacent to 
granular cells of the dentate fascia of the hippocampus.
200µm
Table 1. Clinical data and ancillary tests from seven patients with Gerstmann-Sträussler-Scheinker.
Variable Family A Family B
Patients IIIa -1 IIa - 1 IIa – 2 IIIa – 2 IIa-3 IIIb -1 IIIb - 2
Sex F M F F F F M
Age at onset (y) 27 53 54 38 66 35 25
Onset symptoms
Dementia + + - - - + -
Ataxia - - + + - - +
Paresthesias - - - + + - -
Social withdrawal - - - - + - -
Age at death (y) 42 53 58 45 Living Living Living
Disease duration (y) 15 08/12 4 7 2 4 8
Dementia + + + + + + +
Pyramidal syndrome + - + + - + +
Parkinsonian syndrome + + + - - - -
Cerebellar syndrome - - + + + + +
Myoclonus + + + - - - -
Epilepsy - - + + - - -
Brain MRI
Cerebellar 
and cerebral 
atrophy 
Frontal  
atrophy 
Cerebral atrophy, 
DWI frontal and 
parietal cortex 
hyperintensities  
Cerebellar and 
cerebral atrophy 
Leukoaraiosis 
Cerebellar 
and cerebral 
atrophy 
Cerebellar 
and cerebral 
atrophy 
Frontal 
hypoperfusion 
Cerebellar 
vermis 
hypoperfusion 
Brain SPECT
EEG PSD - - - - - - -
CSF 14.3.3 protein - ND ND ND ND - ND
PRNP gene analysis
Codon 102 Pro/Leu ND Pro/Leu Pro/Leu Pro/Leu Pro/Leu Pro/Leu
Codon 129 Met/Val ND Met/Met Met/Val Met/Met Met/Val Met/Val
Leu102 in cis with Met129 ND Met129 Met129 Met129 Val129 Val129
ApoE gene analysis e2/e3 ND e2/e3 e2/e3 e2/e3 e3/e3 e3/e3
Neuropathological data + + ND + ND ND ND
(-) absent; (+) present; ND: not done; PSD: periodic synchronous discharge; DWI: diffusion weighted imaging; MRI: magnetic resonance imaging; SPECT: single 
photon emission computed tomography; M: methionine; V: valine. EEG: electroencephalogram ; CSF: cerebrospinal fluid; PRNP: prion protein gene .
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with hardly any myelin (Figures 5 and 6). Multicentric plaques, 
immunopositive for PrPSc (Figure 7), some of them containing 
amyloid material, confirmed with Congo Red staining, were 
observed in the cerebral and cerebellar cortex. 
DISCUSSION
The p.Pro102Leu variant is the most frequent mutation 
associated with GSS and has been reported in a number 
of kindreds from Austria, Germany, China, Japan, UK, Italy, 
Argentina and USA families14,19,20.
Classically, GSS with the p.Pro102Leu mutation is char-
acterized by slowly progressive cerebellar ataxia with symp-
tom onset in the fifth or sixth decade of life. During the course 
of the disease, pyramidal signs and cognitive decline are com-
mon. Movement disorders, typically myoclonus and athetosis, 
may occur. Seizures, deafness and cranial nerve palsies number 
among the less common features9. Mean survival of GSS is from 
five to seven years, longer than seen in other prion diseases. Of 
the seven individuals from two families reported herein, four 
died, within eight months, four, seven and 15 years of disease 
onset, respectively. Survival of longer than 10 years is uncommon 
and the longest reported disease duration, so far, was 13 years9. 
The clinical phenotype of GSS disease ranges from ataxia 
followed by dementia to primary cognitive decline, while the 
disease progression rate also varies considerably. Phenotypic 
variability has been reported in other series and appears to 
be unrelated to the p.Met129Val variant genotype21. Patients 
IIIa - 1 and IIIb - 1 had cognitive decline as the first symptom 
and exhibited very early onset, which is unusual but consis-
tent with some other previous reports13. One patient presented 
with clinical features of CJD (patient IIa - 1), while another had 
rapidly-progressively dementia with a long survival (patient 
IIIa - 1). Many studies support the existence of three demen-
tia phenotypes associated with the p.Pro102Leu variant: rapid 
global dementia resembling CJD21,22, slowly progressive cogni-
tive decline23 and frontotemporal type dementia24. 
In the largest published investigation involving 84 GSS indi-
viduals belonging to the same extended family, methionine 
homozygosity at codon 129 was associated with early-onset 
disease while other combinations were not associated with 
disease duration14. In contrast to this recent data, the earliest 
clinical onsets in the present study occurred in four patients 
(IIIa - 1, IIIa - 2, IIIb - 1 and IIIb – 2) heterozygous at codon 129, 
and the p.Pro102Leu  mutation was located in the 129M allele 
for family A and the 129V allele in family B. Besides the age at 
onset and duration of the disease, other phenotypic differences 
were observed among the patients described.
Similar clinical contrasts, with different phenotypes 
within the same family, have been reported worldwide. 
The causes of phenotypic variability within a family with 
GSS mutation are unknown. The polymorphism at codon 
129 alone is probably not the only explanation for the 
pathologic and clinical heterogeneity in GSS (codon 102 
mutation)21. However, they are of particular interest in 
the study of prion diseases since they point to other, as 
yet unknown, factors that may contribute to the diverse 
phenotype associated with the same mutation at PRNP. 
In family A, disease symptoms first manifested at 27 years 
old in the index case, whereas, in her mother the symp-
toms were only reported at the age of 66. 
Another genetic factor that could explain some clinical 
heterogeneity in prion diseases is the apoE polymorphism. 
Conflicting results for the association of sporadic CJD and 
the presence of apoE e4 have been published. Although apoE 
and PRNP may represent effect size of risk association in 
patients with sporadic CJD and e2 carriers have late onset 
disease25, few data supports that apoE is not a risk factor for 
p.Pro102Leu GSS26. However, e4 carriers had delayed age of 
onset by 10 years in the largest GSS kindred studied so far14. 
In our study, there were no e4 carriers and no difference in 
apoE polymorphism among patients in the same family. 
Indeed, these polymorphisms could not explain the clinical 
variability in the kindreds we are describing. 
The presence of CSF 14-3-3 and the occurrence of periodic 
synchronous discharge is unusual in GSS patients and may be 
Figure 4. Patient IIIa-2. Severe diffuse cerebral (a) and cerebellar (b) cortical atrophy, in addition to extensive involvement of the 
subjacent white matter.
A B
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confounding factors in some cases, leading to CJD misdiagno-
sis14. In our sample, all the patients had an electroencephalo-
gram, but none of them had periodic synchronous discharge. 
Two patients had CSF analysis, but they were negative for 14-3-3. 
The pathognomonic neuropathological characteristic 
of GSS is the presence of multicentric amyloid plaques with 
positive PrPc immunoreactivity. Other pathologic features that 
can be found in GSS include gliosis, neuronal loss, neurofibril-
lary tangles and spongiform changes27. The degree of spongiform 
change is variable, and an absence of spongiosis in brain tissue, 
which is uncommon in prion diseases, has been reported11. 
White matter degeneration, as observed in one of the present 
cases, may reflect the degree of neuronal loss, rapidly progressive 
course and/or longer survival in some cases and is described as 
the panencephalopathic form of prion disease28, and has been 
previously reported in one patient with GSS29. 
There is evidence that, besides the mutant isoform, the 
protease-resistant wild-type PrP may also be found in cere-
bral tissue of patients with GSS16. The frequency and spatial 
distribution of both PrPs could offer another explanation for 
the variability in clinical and pathological findings between 
individuals in the same family16. Atypical p.Pro102Leu phe-
notypes are associated with high levels of protease-resistant 
wild-type PrP in few cases. In the present study, we could nei-
ther verify the distribution of different forms of PrP, nor of the 
two abnormal fragments of ~21-30 kDa or 8 kDa.
In family A, third-generation patients presented with 
symptoms earlier than second-generation, suggesting genetic 
anticipation. However, a recent report ruled out this genetic 
phenomenon in prion diseases30. 
Figure 6. (A, B and C) Patient IIIa-2. Multicentric plaques, immunopositive for PrPSc observed in the cerebral cortex.
2mm 700µm 100µm
A B C
Figure 7. Patient IIIa-2. Cerebellar white matter was rarefied (A) and the cortex contained multicentric plaques (B).
3mm 100µm
A B
Figure 5. Patient IIIa-2. Cerebral white matter rarefied, with 
hardly any myelin.
2mm
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It is noteworthy that MRI findings also differ between 
GSS patients. Neuroimaging studies are typically described 
as normal or with non-specific atrophy of cerebral hemi-
spheres and/or cerebellum9. There are, however, few reports 
of cortical and basal ganglia hyperintensities on diffusion-
weighted-MRI during the disease course31,32, as disclosed in 
patient IIa-2. 
In conclusion, the two Brazilian families with GSS asso-
ciated with p.Pro102Leu mutation showed similar clinical 
heterogeneity to other cases described worldwide. However, 
these results failed to corroborate the hypothesis that phe-
notype variation is attributable to polymorphism at codon 
12914,15. Indeed, genomic and epigenetic variations within this 
family warrant further investigation. 
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